Navigation Links
Peregrine Pharmaceuticals Awarded Two New U.S. Patents Broadening Its Targeted Anti-Phospholipid Patent Portfolio
Date:6/16/2008

- New Claims Cover Anti-Viral Applications of Novel Targeted Agents Under

the Company's Anti-Phospholipid Technology Platform - - Anti-Viral Potential of These New Agents Supported by Recent Studies

Presented at American Association of Immunologists Annual Meeting -

TUSTIN, Calif., June 16 /PRNewswire-FirstCall/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM), a clinical stage biopharmaceutical company developing monoclonal antibodies for the treatment of cancer and hepatitis C virus infection (HCV), today reported the issuance of two U.S. patents that significantly broaden the company's intellectual property leadership in the field of targeted anti-aminophospholipid agents. The new patents grant Peregrine broad anti-viral method claims using a range of phosphatidylethanolamine (PE) binding agents, including PE-binding peptides attached to anti-viral agents as well as those conjugated to antibodies or other substances.

"These are significant patents for Peregrine that substantially expand our intellectual property portfolio in the field of aminophospholipid-targeting agents," said Dr. Shelley Fussey, vice president of intellectual property at Peregrine. "These anti-PE agents appear to have anti-viral properties similar to the anti-phosphatidylserine (PS) monoclonal antibody bavituximab that we currently are testing in clinical trials in HCV patients and in preclinical studies for HIV and other viral infections. We are especially pleased at the breadth of the issued claims, which provide Peregrine with U.S. patent coverage for methods of combating all relevant viruses using the claimed anti-PE peptide conjugates, either used alone or in combination with other anti-viral drugs. As peptide conjugates, anti-
'/>"/>

SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Data To Be Presented at ASCO Supports Potential of Peregrines Cotara(R) for the Treatment of Brain Cancer
2. Peregrine Pharmaceuticals Completes Patient Enrollment in First Stage of Bavituximab Phase II Breast Cancer Trial
3. Peregrine Researchers Present New Preclinical Data at AACR Annual Meeting Confirming Unique Anti-Tumor Mechanism of Bavituximab
4. Preclinical Study Presented at AACR Annual Meeting Shows Peregrines Anti-PS Immunocytokines Can Generate Protective Immune Responses in a Highly Aggressive Breast Cancer Model
5. Preclinical Study Presented at AACR Annual Meeting Shows Broad Anti-Cancer Potential of Peregrines anti-PS Vascular Targeting Antibodies
6. Clinical Experience With Peregrines Anti-Cancer Agent Bavituximab Presented at Leading Symposium on Anti-Angiogenic Agents
7. Peregrine Pharmaceuticals Opens Enrollment in Phase II Clinical Trial of Bavituximab in Patients with Advanced Breast Cancer
8. Peregrine Pharmaceuticals Receives Approval to Conduct a Second Phase II Trial of Bavituximab in Patients With Advanced Breast Cancer
9. Peregrine Pharmaceuticals Receives Approval to Conduct a Phase II Trial of Bavituximab in Patients With Non-Small Cell Lung Cancer
10. Peregrine Announces Addition of The Johns Hopkins Hospital as Study Site for Bavituximab Trial in HCV Patients Co-Infected With HIV
11. New Data Confirms That a Selective, Fully Human Anti-VEGF Antibody Being Developed by Peregrine is as Effective as Avastin(R) in Preclinical Cancer Models
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/17/2014)... 2014 Research and Markets  has ... Development Prospect of China Dialysis Market, 2014-2018" ... on the 2013 version, this update Report provides ... industry and the relevant effect in recent three ... segmentations. Moreover, it analyzes Chinese private-owned hemodialysis services. ...
(Date:10/17/2014)... 2014 Investor-Edge has initiated coverage ... ARNA ), NPS Pharmaceuticals Inc. (NASDAQ: ... Momenta Pharmaceuticals Inc. (NASDAQ: MNTA ), and ... these five companies can be accessed at: http://investor-edge.com/register ... 16, 2014, ended on a mixed note as the ...
(Date:10/17/2014)... 17, 2014   InnFocus, Inc ., reported on results ... States for up to 3 years with the ... in Chicago . The Summit ... annual meeting of the American Academy of Ophthalmology . ... 150 glaucoma patients in 6 countries by early 2015. ...
Breaking Medicine Technology:Research and Development Prospect of China Dialysis Market, 2014-2018 2Research and Development Prospect of China Dialysis Market, 2014-2018 3Biotech Equities Technical Briefing - Arena Pharma, NPS Pharma, XOMA, Momenta Pharma, and Catalyst Pharma Partners 2Biotech Equities Technical Briefing - Arena Pharma, NPS Pharma, XOMA, Momenta Pharma, and Catalyst Pharma Partners 3Biotech Equities Technical Briefing - Arena Pharma, NPS Pharma, XOMA, Momenta Pharma, and Catalyst Pharma Partners 4Biotech Equities Technical Briefing - Arena Pharma, NPS Pharma, XOMA, Momenta Pharma, and Catalyst Pharma Partners 5InnFocus Featured at the Ophthalmology Innovation Summit In Chicago 2
... Sept. 27, 2011 Thousands of jobs in Michigan ... if harmful policies – such as imposing new taxes ... by federal policymakers. From research to technical ... suppliers to child care services, the biopharmaceutical sector supports ...
... in Texas supported by the biopharmaceutical research sector would ... new taxes in the Medicare prescription drug program – ... to technical work, manufacturing to construction and other building ... sector supports a broad array of high-quality jobs. ...
Cached Medicine Technology:Research Demonstrates Possible Michigan Job Losses from Sectors Supported by Biopharmaceutical Companies 2Research Demonstrates Possible Michigan Job Losses from Sectors Supported by Biopharmaceutical Companies 3Research Demonstrates Possible Texas Job Losses from Sectors Supported by Biopharmaceutical Companies 2Research Demonstrates Possible Texas Job Losses from Sectors Supported by Biopharmaceutical Companies 3
(Date:10/20/2014)... San Diego, CA (PRWEB) October 20, 2014 ... regarding all the latest information from the FDA on ... consumers on October 10 not to purchase or use Sit ... Phenolphthalein. Sit and Slim II is promoted as weight loss ... , Sibutramine, removed from the market in 2010 for safety ...
(Date:10/20/2014)... National Teen Driver Safety Week is October 19-25, ... Pediatrics (Ohio AAP, http://www.ohioaap.org ) is joining the National ... drivers to talk to their teens and always set the ... are the leading cause of death for U.S. teens. In ... and 859 (42%) of those teen drivers were killed in ...
(Date:10/20/2014)... Houston, Texas (PRWEB) October 20, 2014 ... invited to present the key elements of his innovative ... visiting professor to plastic surgery residents and faculty at ... (UTMB) , where he, too, was once a medical ... of the largest private cosmetic plastic surgery practices in ...
(Date:10/19/2014)... 2014 Dr. Babatunde Osotimehin, Executive Director ... of a ceasefire agreement that is expected to lead ... who were kidnapped from the north-eastern Nigerian town of ... long enough, and it is high time they are ... Osotimehin. , "We owe it to these girls to ...
(Date:10/19/2014)... 20, 2014 SweetDressy.com, a professional company ... its promotion for long evening dresses . All ... special offer; the current discount is up to 66 ... industry pioneers in the fashion field. Its dress specialists ... dwelling in various parts of the world. All the ...
Breaking Medicine News(10 mins):Health News:FDA Advises Not to Use Sit and Slim II: AttorneyOne Monitors and Keeps Consumers Informed 2Health News:Ohio AAP Promotes National Teen Driver Safety Week 2Health News:Plastic Surgeon Patronella Presents Artistically-Inspired Tummy Tuck Method to Future Generation of Plastic Surgeons in Texas 2Health News:Promotion For Beautiful Long Evening Dresses Launched By SweetDressy.com 2
... better understand where to focus efforts to ... CAMBRIDGE, MA, May 28 /PRNewswire/ - rL ... software that helps organizations manage,infection control issues, patient ... claims and quality issues,announced today that Caritas Christi ...
... N.C., May 28 Take advantage of quick ... attend the 10th Annual Human,Resources Conference: Leadership Development ... full conference agenda at, http://www3.best-in-class.com/gr163.htm ), sponsored ... 2008, at The Ritz-Carlton,Hotel, Sarasota, Fla., Registration ...
... TV Leader Guthy-Renker Attracts yet Another Celebrity for ... America,s Best-Selling Acne ... announced,today that Ryan Sheckler, famed skateboarder and television star, ... acne treatment,Proactiv Solution. Known for its wide range of ...
... Million Home-Device Market With First-to-Market ... Technology, Strong Branding, ... series of corporate milestones in anticipation of FDA clearance,for CLARO, ... the appointment of a senior marketing,executive, expansion of the Board ...
... 28 Shamir Optical,Industry Ltd. (Nasdaq: SHMR ) ... the progressive ophthalmic lens market, today,announced unaudited financial results ... the quarter ended March 31, 2008, revenues increased 29.5% ... the same period of 2007.,Gross profit for the quarter ...
... LOS ANGELES, May 28 5-year-old Noor came to,the ... Division,s 1st,Battalion, 30th Infantry Regiment, 2nd Brigade Combat Team ... that resulted,in the death of the little girl,s uncle. ... battalion surgeon, concluded that Noor is blind,due to a ...
Cached Medicine News:Health News:Caritas Christi Standardizes on rL Solutions to Help Deliver Best in Class Healthcare Quality 2Health News:Registration Ends This Week: Fortune 500 Networking & Best Practice Sharing Conference in Florida 2Health News:Professional Skateboarder Ryan Sheckler to Become the Newest Face of Proactiv Solution 2Health News:Professional Skateboarder Ryan Sheckler to Become the Newest Face of Proactiv Solution 3Health News:CLRS Technology Accelerates Infrastructure Growth Anticipating FDA Clearance for At-Home IPL Acne Device 2Health News:CLRS Technology Accelerates Infrastructure Growth Anticipating FDA Clearance for At-Home IPL Acne Device 3Health News:Shamir Optical Industry Ltd. Reports First Quarter 2008 Results 2Health News:Shamir Optical Industry Ltd. Reports First Quarter 2008 Results 3Health News:Shamir Optical Industry Ltd. Reports First Quarter 2008 Results 4Health News:Shamir Optical Industry Ltd. Reports First Quarter 2008 Results 5Health News:Shamir Optical Industry Ltd. Reports First Quarter 2008 Results 6Health News:Shamir Optical Industry Ltd. Reports First Quarter 2008 Results 7Health News:Shamir Optical Industry Ltd. Reports First Quarter 2008 Results 8Health News:Shamir Optical Industry Ltd. Reports First Quarter 2008 Results 9Health News:Photos: Los Angeles Non Profit Teams With US Troops Stationed in Baghdad and Buaytha in Bringing a 5-Year-Old Blind Iraqi Girl, Whose Father Stands Beside US Combat Team Against Al Qaeda, to the US for a Groundbreaking Artificial Corneal Transplant Surger 2
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: